Pfizer Inc. (PFE) 10-Year Financial Performance & Capital Metrics

PFE • • Industrial / General

HealthcareLarge PharmaBroad-Based Pharmaceutical GiantsGlobal Pharma Diversified Leaders

AboutPfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.Show more

Revenue $63.63B +6.8%
EBITDA $23.5B +102.9%
Net Income $8.02B +276.0%
EPS (Diluted) 1.41 +279.8%
Gross Margin 65.77% +29.1%
EBITDA Margin 36.93% +89.9%
Operating Margin 25.91% +191.5%
Net Margin 12.6% +251.9%
ROE 9.02% +291.7%
ROIC 7.93% +187.4%
Debt/Equity 0.76 -4.6%
Interest Coverage 5.33 +122.6%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Strong Piotroski F-Score: 8/9
✓FCF machine: 15.5% free cash flow margin
✓14 consecutive years of dividend growth
✓High quality earnings: Operating CF exceeds net income
✓Good 3Y average ROE of 15.8%
✓Healthy 5Y average net margin of 19.3%

✗Weaknesses

✗Profits declining 13.2% over 5 years
✗Dividend payout exceeds 100% of earnings
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y2.52%

5Y9.1%

3Y-7.84%

TTM3.89%

Profit (Net Income) CAGR

10Y-1.23%

5Y-13.2%

3Y-28.72%

TTM129.78%

EPS CAGR

10Y-0.02%

5Y-13.24%

3Y-28.64%

TTM132.86%

ROCE

10Y Avg10.77%

5Y Avg12.15%

3Y Avg12.72%

Latest9.44%

Peer Comparison

Global Pharma Diversified Leaders

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
AZNAstraZeneca PLC	293.03B	94.51	83.64	18.04%	16.17%	20.45%	2.48%	0.74
GSKGSK plc	100.65B	49.90	40.24	3.46%	17.08%	25.91%	3.55%	1.30
JNJJohnson & Johnson	514.75B	213.65	36.90	4.3%	27.26%	31.69%	3.85%	0.53
NVSNovartis AG	271.72B	141.61	24.12	10.85%	25.53%	32.16%	5.08%	0.71
SNYSanofi	114.36B	47.20	21.55	6.41%	21.16%	12.99%	5.15%	0.23
PFEPfizer Inc.	143B	25.15	17.84	6.84%	15.64%	10.55%	6.88%	0.76
MRKMerck & Co., Inc.	268.7B	108.26	16.06	6.74%	29.63%	36.67%	6.73%	0.83

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	48.85B	52.82B	52.55B	53.65B	41.17B	41.65B	81.29B	100.33B	59.55B	63.63B
Revenue Growth %	-0.02%	0.08%	-0.01%	0.02%	-0.23%	0.01%	0.95%	0.23%	-0.41%	0.07%
Cost of Goods Sold+	13.16B	15.95B	15.78B	16.01B	12.62B	11.77B	34.41B	38.24B	29.21B	21.78B
COGS % of Revenue	0.27%	0.3%	0.3%	0.3%	0.31%	0.28%	0.42%	0.38%	0.49%	0.34%
Gross Profit+	35.69B	36.87B	36.77B	37.64B	28.55B	29.88B	46.88B	62.09B	30.34B	41.85B
Gross Margin %	0.73%	0.7%	0.7%	0.7%	0.69%	0.72%	0.58%	0.62%	0.51%	0.66%
Gross Profit Growth %	-0.02%	0.03%	-0%	0.02%	-0.24%	0.05%	0.57%	0.32%	-0.51%	0.38%
Operating Expenses+	22.4B	22.6B	22.38B	22.35B	21.04B	20.8B	26.08B	24.54B	25.05B	25.36B
OpEx % of Revenue	0.46%	0.43%	0.43%	0.42%	0.51%	0.5%	0.32%	0.24%	0.42%	0.4%
Selling, General & Admin	14.73B	14.76B	14.73B	14.38B	12.67B	11.4B	12.25B	13.12B	14.47B	14.73B
SG&A % of Revenue	0.3%	0.28%	0.28%	0.27%	0.31%	0.27%	0.15%	0.13%	0.24%	0.23%
Research & Development	7.67B	7.84B	7.64B	7.97B	8.36B	9.39B	13.83B	11.43B	10.58B	10.74B
R&D % of Revenue	0.16%	0.15%	0.15%	0.15%	0.2%	0.23%	0.17%	0.11%	0.18%	0.17%
Other Operating Expenses	0	0	0	0	0	0	0	0	0	-105M
Operating Income+	13.3B	14.27B	14.39B	15.29B	7.51B	9.09B	20.79B	37.55B	5.29B	16.48B
Operating Margin %	0.27%	0.27%	0.27%	0.28%	0.18%	0.22%	0.26%	0.37%	0.09%	0.26%
Operating Income Growth %	-0.05%	0.07%	0.01%	0.06%	-0.51%	0.21%	1.29%	0.81%	-0.86%	2.11%
EBITDA+	18.45B	20.03B	20.66B	21.67B	13.31B	13.77B	25.98B	42.61B	11.58B	23.5B
EBITDA Margin %	0.38%	0.38%	0.39%	0.4%	0.32%	0.33%	0.32%	0.42%	0.19%	0.37%
EBITDA Growth %	-0.06%	0.09%	0.03%	0.05%	-0.39%	0.03%	0.89%	0.64%	-0.73%	1.03%
D&A (Non-Cash Add-back)	5.16B	5.76B	6.27B	6.38B	5.79B	4.68B	5.19B	5.06B	6.29B	7.01B
EBIT	10.16B	9.54B	13.57B	13.2B	13.06B	8.49B	25.6B	35.97B	3.27B	11.11B
Net Interest Income+	-728M	-716M	-879M	-983M	-1.35B	-1.38B	-1.25B	-987M	-585M	-2.55B
Interest Income	471M	470M	391M	333M	225M	73M	36M	251M	1.62B	545M
Interest Expense	1.2B	1.19B	1.27B	1.32B	1.57B	1.45B	1.29B	1.24B	2.21B	3.09B
Other Income/Expense	-4.33B	-5.92B	-2.09B	-3.4B	3.97B	-2.05B	3.52B	-2.82B	-4.23B	-8.46B
Pretax Income+	8.96B	8.35B	12.3B	11.88B	11.48B	7.04B	24.31B	34.73B	1.06B	8.02B
Pretax Margin %	0.18%	0.16%	0.23%	0.22%	0.28%	0.17%	0.3%	0.35%	0.02%	0.13%
Income Tax+	1.99B	1.12B	-9.05B	706M	618M	370M	1.85B	3.33B	-1.11B	-28M
Effective Tax Rate %	0.78%	0.86%	1.73%	0.94%	1.42%	1.3%	0.91%	0.9%	2.02%	1%
Net Income+	6.97B	7.21B	21.3B	11.15B	16.27B	9.16B	22.15B	31.36B	2.13B	8.02B
Net Margin %	0.14%	0.14%	0.41%	0.21%	0.4%	0.22%	0.27%	0.31%	0.04%	0.13%
Net Income Growth %	-0.23%	0.04%	1.95%	-0.48%	0.46%	-0.44%	1.42%	0.42%	-0.93%	2.76%
Net Income (Continuing)	6.97B	7.23B	21.35B	11.18B	10.87B	6.67B	22.46B	31.4B	2.17B	8.05B
Discontinued Operations	17M	17M	-1M	10M	5.43B	2.53B	-268M	-1M	0	11M
Minority Interest	278M	296M	348M	351M	303M	235M	262M	256M	274M	294M
EPS (Diluted)+	1.11	1.17	3.52	1.87	2.87	1.63	3.88	5.47	0.37	1.41
EPS Growth %	-0.21%	0.05%	2.01%	-0.47%	0.54%	-0.43%	1.39%	0.41%	-0.93%	2.8%
EPS (Basic)	1.13	1.18	3.57	1.90	2.92	1.65	3.95	5.59	0.38	1.42
Diluted Shares Outstanding	6.26B	6.16B	6.06B	5.98B	5.67B	5.63B	5.71B	5.73B	5.71B	5.7B
Basic Shares Outstanding	6.18B	6.09B	5.97B	5.87B	5.57B	5.55B	5.6B	5.61B	5.64B	5.66B
Dividend Payout Ratio	1%	1.01%	0.36%	0.72%	0.49%	0.92%	0.39%	0.29%	4.34%	1.19%

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	43.8B	38.95B	41.14B	49.93B	32.8B	35.07B	59.69B	51.26B	43.33B	50.36B
Cash & Short-Term Investments	23.29B	17.85B	19.99B	18.83B	9.65B	12.22B	31.07B	22.73B	12.69B	20.48B
Cash Only	3.64B	2.6B	1.34B	1.14B	1.12B	1.79B	1.94B	416M	2.85B	1.04B
Short-Term Investments	19.65B	15.26B	18.65B	17.69B	8.53B	10.44B	29.13B	22.32B	9.84B	19.43B
Accounts Receivable	10.84B	11.27B	11.27B	11.4B	9.51B	11.18B	15.74B	14.53B	15.54B	14.78B
Days Sales Outstanding	80.98	77.85	78.29	77.56	84.29	97.95	70.7	52.86	95.27	84.77
Inventory	7.51B	6.78B	7.58B	7.51B	7.07B	8.05B	9.06B	8.98B	10.19B	10.85B
Days Inventory Outstanding	208.42	155.18	175.32	171.19	204.37	249.49	96.08	85.72	127.31	181.84
Other Current Assets	2.16B	3.05B	2.3B	12.19B	6.58B	3.65B	3.82B	5.02B	4.91B	4.25B
Total Non-Current Assets+	123.66B	132.67B	130.65B	109.5B	134.69B	119.16B	121.78B	145.94B	183.17B	163.04B
Property, Plant & Equipment	13.77B	13.32B	13.87B	13.38B	12.97B	13.74B	14.88B	16.27B	18.94B	18.39B
Fixed Asset Turnover	3.55x	3.97x	3.79x	4.01x	3.17x	3.03x	5.46x	6.17x	3.14x	3.46x
Goodwill	48.24B	54.45B	55.95B	53.41B	48.2B	49.56B	49.21B	51.38B	67.78B	68.53B
Intangible Assets	40.36B	52.65B	48.74B	35.21B	33.94B	28.34B	25.15B	43.37B	64.9B	55.41B
Long-Term Investments	16B	7.12B	7.01B	2.77B	20.15B	20.26B	21.53B	15.07B	15.37B	2.23B
Other Non-Current Assets	3.5B	3.32B	3.23B	2.8B	17.63B	4.57B	7.68B	13.16B	12.47B	9.82B
Total Assets+	167.46B	171.62B	171.8B	159.42B	167.49B	154.23B	181.48B	197.21B	226.5B	213.4B
Asset Turnover	0.29x	0.31x	0.31x	0.34x	0.25x	0.27x	0.45x	0.51x	0.26x	0.30x
Asset Growth %	-0.01%	0.02%	0%	-0.07%	0.05%	-0.08%	0.18%	0.09%	0.15%	-0.06%
Total Current Liabilities+	29.4B	31.11B	30.43B	31.86B	37.3B	25.92B	42.67B	42.14B	47.79B	42.99B
Accounts Payable	3.62B	4.54B	4.66B	4.67B	3.89B	4.28B	5.58B	6.81B	6.71B	5.63B
Days Payables Outstanding	100.43	103.78	107.72	106.57	112.39	132.81	59.16	64.99	83.84	94.4
Short-Term Debt	10.16B	10.66B	9.94B	8.84B	16.19B	2.7B	2.24B	2.93B	10.35B	6.95B
Deferred Revenue (Current)	0	0	0	0	0	1000K	1000K	1000K	1000K	1000K
Other Current Liabilities	13.35B	13.54B	13.32B	15.04B	14.14B	14.61B	28.27B	25.98B	23.32B	23.2B
Current Ratio	1.49x	1.25x	1.35x	1.57x	0.88x	1.35x	1.40x	1.22x	0.91x	1.17x
Quick Ratio	1.23x	1.03x	1.10x	1.33x	0.69x	1.04x	1.19x	1.00x	0.69x	0.92x
Cash Conversion Cycle	188.98	129.25	145.89	142.17	176.27	214.63	107.62	73.59	138.74	172.21
Total Non-Current Liabilities+	72.98B	80.66B	69.71B	63.81B	66.84B	64.84B	61.34B	59.15B	89.42B	81.9B
Long-Term Debt	28.74B	30.4B	32.67B	32.91B	34.65B	35.57B	34.76B	31.93B	60.5B	57.41B
Capital Lease Obligations	-12.11B	-12.17B	-27B	-21.35B	1.03B	0	0	0	0	2.29B
Deferred Tax Liabilities	26.88B	30.75B	3.9B	3.7B	5.58B	4.06B	349M	1.02B	640M	2.12B
Other Non-Current Liabilities	17.37B	19.51B	33.15B	27.2B	26.54B	25.2B	26.24B	26.2B	28.28B	20.09B
Total Liabilities	102.38B	111.78B	100.14B	95.66B	104.15B	90.76B	104.01B	101.29B	137.21B	124.9B
Total Debt+	38.9B	41.06B	42.61B	41.74B	50.84B	38.27B	37B	34.86B	70.84B	66.99B
Net Debt	35.26B	38.47B	41.26B	40.61B	49.72B	36.49B	35.05B	34.44B	67.99B	65.95B
Debt / Equity	0.60x	0.69x	0.59x	0.65x	0.80x	0.60x	0.48x	0.36x	0.79x	0.76x
Debt / EBITDA	2.11x	2.05x	2.06x	1.93x	3.82x	2.78x	1.42x	0.82x	6.12x	2.85x
Net Debt / EBITDA	1.91x	1.92x	2.00x	1.87x	3.74x	2.65x	1.35x	0.81x	5.87x	2.81x
Interest Coverage	11.09x	12.04x	11.33x	11.62x	4.77x	6.27x	16.11x	30.33x	2.40x	5.33x
Total Equity+	65B	59.84B	71.66B	63.76B	63.45B	63.47B	77.46B	95.92B	89.29B	88.5B
Equity Growth %	-0.09%	-0.08%	0.2%	-0.11%	-0%	0%	0.22%	0.24%	-0.07%	-0.01%
Book Value per Share	10.39	9.72	11.83	10.67	11.18	11.27	13.57	16.73	15.64	15.53
Total Shareholders' Equity	64.72B	59.54B	71.31B	63.41B	63.14B	63.24B	77.2B	95.66B	89.01B	88.2B
Common Stock	459M	461M	464M	467M	468M	470M	473M	476M	478M	480M
Retained Earnings	71.99B	71.77B	85.29B	89.55B	97.67B	96.77B	103.39B	125.66B	118.35B	116.72B
Treasury Stock	-79.25B	-84.36B	-89.42B	-101.61B	-110.8B	-110.99B	-111.36B	-113.97B	-114.49B	-114.76B
Accumulated OCI	-9.52B	-11.04B	-9.32B	-11.28B	-11.64B	-11.69B	-5.9B	-8.3B	-7.96B	-7.84B
Minority Interest	278M	296M	348M	351M	303M	235M	262M	256M	274M	294M

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	14.51B	15.9B	16.47B	15.83B	12.59B	14.4B	32.58B	29.27B	8.7B	12.74B
Operating CF Margin %	0.3%	0.3%	0.31%	0.3%	0.31%	0.35%	0.4%	0.29%	0.15%	0.2%
Operating CF Growth %	-0.14%	0.1%	0.04%	-0.04%	-0.2%	0.14%	1.26%	-0.1%	-0.7%	0.46%
Net Income	6.99B	7.25B	21.36B	11.19B	16.3B	7.02B	22.46B	31.4B	2.17B	8.05B
Depreciation & Amortization	5.16B	5.76B	6.27B	6.38B	6.01B	4.78B	5.19B	5.06B	6.29B	7.01B
Stock-Based Compensation	669M	691M	840M	949M	718M	756M	1.18B	872M	525M	877M
Deferred Taxes	-18M	-700M	-2.41B	-2.21B	614M	-1.47B	-4.29B	-3.76B	-3.44B	-2.1B
Other Non-Cash Items	1.15B	2.82B	-10.88B	437M	-7.03B	3.59B	-4.76B	150M	5.33B	1.97B
Working Capital Changes	564M	85M	1.3B	-926M	-4.03B	-275M	12.8B	-4.46B	-2.17B	-3.07B
Change in Receivables	21M	-134M	259M	-644M	-742M	-1.25B	-3.81B	261M	347M	-109M
Change in Inventory	-199M	365M	-357M	-717M	-1.05B	-736M	-1.13B	592M	6.2B	-854M
Change in Payables	254M	871M	46M	431M	-564M	353M	1.24B	1.19B	-300M	-1.02B
Cash from Investing+	-2.98B	-7.81B	-4.74B	4.53B	-3.94B	-4.27B	-22.55B	-15.78B	-32.28B	2.65B
Capital Expenditures	-1.5B	-2B	-2.22B	-2.2B	-2.59B	-2.79B	-2.71B	-3.24B	-3.91B	-2.91B
CapEx % of Revenue	0.03%	0.04%	0.04%	0.04%	0.06%	0.07%	0.03%	0.03%	0.07%	0.05%
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	344M	52M	650M	133M	206M	813M	-306M	3.77B	-180M	0
Cash from Financing+	-10.23B	-8.92B	-13.04B	-20.44B	-8.48B	-9.65B	-9.82B	-14.83B	26.07B	-17.14B
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	-6.94B	-7.32B	-7.66B	-7.98B	-8.04B	-8.44B	-8.73B	-8.98B	-9.25B	-9.51B
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	1.37B	-229M	250M	-589M	-341M	11.55B	16M	-335M	-632M	-469M
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	13.02B	13.9B	14.25B	13.63B	9.99B	11.61B	29.87B	26.03B	4.79B	9.84B
FCF Margin %	0.27%	0.26%	0.27%	0.25%	0.24%	0.28%	0.37%	0.26%	0.08%	0.15%
FCF Growth %	-0.15%	0.07%	0.03%	-0.04%	-0.27%	0.16%	1.57%	-0.13%	-0.82%	1.05%
FCF per Share	2.08	2.26	2.35	2.28	1.76	2.06	5.23	4.54	0.84	1.73
FCF Conversion (FCF/Net Income)	2.08x	2.20x	0.77x	1.42x	0.77x	1.57x	1.47x	0.93x	4.08x	1.59x
Interest Paid	1.3B	1.45B	1.52B	1.31B	1.59B	1.64B	1.47B	1.44B	2.21B	3.23B
Taxes Paid	2.38B	2.52B	2.49B	3.65B	3.66B	3.15B	7.43B	7.87B	3.15B	3.6B

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	10.2%	11.56%	32.4%	16.47%	25.59%	14.43%	31.43%	36.18%	2.3%	9.02%
Return on Invested Capital (ROIC)	9.72%	10.78%	10.22%	10.55%	5.18%	6.39%	14.68%	23.19%	2.76%	7.93%
Gross Margin	73.07%	69.8%	69.97%	70.16%	69.34%	71.74%	57.67%	61.89%	50.95%	65.77%
Net Margin	14.26%	13.66%	40.55%	20.79%	39.52%	21.99%	27.25%	31.26%	3.58%	12.6%
Debt / Equity	0.60x	0.69x	0.59x	0.65x	0.80x	0.60x	0.48x	0.36x	0.79x	0.76x
Interest Coverage	11.09x	12.04x	11.33x	11.62x	4.77x	6.27x	16.11x	30.33x	2.40x	5.33x
FCF Conversion	2.08x	2.20x	0.77x	1.42x	0.77x	1.57x	1.47x	0.93x	4.08x	1.59x
Revenue Growth	-1.52%	8.13%	-0.53%	2.1%	-23.25%	1.16%	95.16%	23.43%	-40.64%	6.84%

Revenue by Segment

	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Biopharma	-	-	-	-	39.42B	-	79.56B	98.99B	57.19B	62.4B
Biopharma Growth	-	-	-	-	-	-	-	24.42%	-42.23%	9.12%
Business Innovation	-	-	-	-	-	-	-	-	1.31B	-
Business Innovation Growth	-	-	-	-	-	-	-	-	-	-
Upjohn	-	-	-	-	10.23B	-	-	-	-	-
Upjohn Growth	-	-	-	-	-	-	-	-	-	-
Innovative Health	-	29.2B	31.42B	33.43B	-	-	-	-	-	-
Innovative Health Growth	-	-	7.62%	6.38%	-	-	-	-	-	-
Essential Health	-	23.63B	21.12B	20.22B	-	-	-	-	-	-
Essential Health Growth	-	-	-10.59%	-4.27%	-	-	-	-	-	-
Global Established Pharmaceutical	21.59B	-	-	-	-	-	-	-	-	-
Global Established Pharmaceutical Growth	-	-	-	-	-	-	-	-	-	-
Global Innovative Pharmaceutical	13.95B	-	-	-	-	-	-	-	-	-
Global Innovative Pharmaceutical Growth	-	-	-	-	-	-	-	-	-	-
Global Vaccines, Oncology and Consumer Healthcare	12.8B	-	-	-	-	-	-	-	-	-
Global Vaccines, Oncology and Consumer Healthcare Growth	-	-	-	-	-	-	-	-	-	-

Revenue by Geography

	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
UNITED STATES	21.7B	26.37B	26.03B	25.33B	23.85B	21.71B	29.75B	42.47B	27.09B	38.69B
UNITED STATES Growth	-	21.49%	-1.30%	-2.68%	-5.83%	-8.97%	37.00%	42.79%	-36.22%	42.83%
Developed Rest Of World	6.3B	6.73B	6.61B	6.55B	6.46B	4.04B	12.51B	15.78B	7.76B	16.06B
Developed Rest Of World Growth	-	6.84%	-1.74%	-0.92%	-1.31%	-37.57%	209.86%	26.16%	-50.81%	106.89%
Emerging Markets	11.14B	10.42B	11.4B	12.65B	12.73B	8.37B	20.7B	20.1B	12B	8.88B
Emerging Markets Growth	-	-6.43%	9.40%	10.98%	0.65%	-34.25%	147.26%	-2.92%	-40.31%	-25.98%
Developed Europe	9.71B	9.31B	8.51B	9.12B	8.7B	7.79B	18.34B	21.98B	11.65B	-
Developed Europe Growth	-	-4.20%	-8.58%	7.15%	-4.55%	-10.49%	135.44%	19.88%	-47.00%	-

Frequently Asked Questions

Valuation & Price

Pfizer Inc. (PFE) has a price-to-earnings (P/E) ratio of 17.8x. This is roughly in line with market averages.

Growth & Financials

Pfizer Inc. (PFE) reported $62.78B in revenue for fiscal year 2024. This represents a 3% increase from $61.03B in 2011.

Pfizer Inc. (PFE) grew revenue by 6.8% over the past year. This is steady growth.

Yes, Pfizer Inc. (PFE) is profitable, generating $9.82B in net income for fiscal year 2024 (12.6% net margin).

Dividend & Returns

Yes, Pfizer Inc. (PFE) pays a dividend with a yield of 6.64%. This makes it attractive for income-focused investors.

Pfizer Inc. (PFE) has a return on equity (ROE) of 9.0%. This is below average, suggesting room for improvement.

Pfizer Inc. (PFE) generated $10.38B in free cash flow for fiscal year 2024. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.

US Stock Screener

...